ERBB2 and triple-negative breast carcinoma: Although the pooled analysis from CTNeoBC did not support pCR as a surrogate endpoint for an improved event-free survival or overall survival in all subtypes of breast cancer [13], pCR was an effective surrogate endpoint for selected patients in aggressive subtypes including luminal B/HER-, HER2 overexpression and triple negative breast cancer [14].